Intensity Therapeutics, a privately held biotechnology company based in Westport, has reported results that demonstrate the ability of the company’s proprietary product, INT230-6, to create a robust anti-cancer immunological effect in a murine model of cancer.

Chief Executive Officer Lewis H. Bender said, “Data suggest that our approach could activate a personalized, systemic immunologic response to attack both the patient’s primary, visible tumors and kill distal cancer metastases to place the patient in remission and prevent disease recurrence.”